Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115728 | 0.98 | L3MBTL1 (0.44) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL7519245 | 0.89 | L3MBTL1 (0.42) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL1115532 | 0.88 | L3MBTL1 (0.41) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| Amotosalen SCHEMBL599618 | 0.85 | MAOA (0.44) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL7000396 | 0.85 | MCL1 (0.41) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL4374604 | 0.85 | MAOA (0.40) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| Amotosalen SCHEMBL4197287 | 0.84 | MAOA (0.43) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL13078690 | 0.84 | MAOA (0.50) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL3359066 | 0.83 | MAOA (0.42) | L3MBTL1MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL21585417 | 0.83 | MAOA (0.42) | L3MBTL1MAOAMAOBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1584622-B1 | Compounds for the photodecontamination of pathogens in blood | CERUS CORP (US) | 2009-11-11 | — | — | EP | claimed |
| EP-1584622-A2 | Compounds for the photodecontamination of pathogens in blood | Cerus Corporation (US) | 2005-10-12 | — | — | EP | claimed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | claimed |
| EP-1584622-B1 | Compounds for the photodecontamination of pathogens in blood | CERUS CORP (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1776952-A2 | Photodecontamination of pathogens in blood | Cerus Corporation (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-0707476-B1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | CERUS CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1584622-A2 | Compounds for the photodecontamination of pathogens in blood | Cerus Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6686480-B2 | PSORALEN COMPOUNDS WITH AMINOALKYL GROUPS ON THE 5' POSITION AND OPTIONAL ALKYL GROUPS ON POSITIONS 4,4' AND 8 THAT BIND TO NUCLEIC ACID OF PATHOGENS, AND UNDER PHOTOACTIVATION CROSSLINK THE NUCLEIC ACID, INACTIVATING THE PATHOGEN | CERUS CORPORATION | 2004-02-03 | — | — | US | disclosed |
| US-20030105339-A1 | Psoralen compounds with aminoalkyl groups on the 5' position and optional alkyl groups on positions 4,4' and 8 that bind to nucleic acid of pathogens, and under photoactivation crosslink the nucleic acid, inactivating the pathogen | CERUS CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-6503699-B1 | Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound | CERUS CORPORATION | 2003-01-07 | — | — | US | disclosed |
| US-6420570-B1 | THE PRESENT INVENTION CONTEMPLATES METHODS OF INACTIVATING MICROORGANISMS IN BLOOD PREPARATIONS, BLOOD PREPARATION SUSPECTED OF BEING CONTAMINATED WITH A PATHOGEN HAVING NUCLEIC ACID | CERUS CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-5972593-A | MIXING COMPOUND WITH BLOOD PREPARATION, THEN PHOTOACTIVATING COMPOUND CAUSING COVALENT BINDING TO MICROORGANISM NUCLEIC ACIDS; HIGHER BINDING LEVELS, LOWER MUTAGENICITY; FOR SAFER, EFFICIENT AND ACCURATE DEACTIVATION | CERUS CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| US-5654443-A | AMINOALKYL SUBSTITUTED PSORALENS WHICH CROSSLINK WITH MICROORGANISM NUCLEIC ACID IN PRESENCE OF LIGHT | CERUS CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5585503-A | PSORALEN COMPOUNDS | STERITECH, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5578736-A | SUBSTITUTED PSORALENS | STERITECH, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5399719-A | 4'-/4-Amino-2-oxa/butyl-4,5',8-trimethylpsoralen; preparation of 4'-/omega-amino-2-oxa/alkyl-4,5',8-trimethylpsoralens by reacting analogous omega-hydroxy compound with methanesulfonyl chloride and base, with sodium azide, with reducing agent | STERITECH, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105339-A1 | Psoralen compounds with aminoalkyl groups on the 5' position and optional alkyl groups on positions 4,4' and 8 that bind to nucleic acid of pathogens, and under photoactivation crosslink the nucleic acid, inactivating the pathogen | PCNA, POLL, ERCC4 | L3MBTL1 800/4885MAOA 3578/4885MAOB 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.